Small molecule drug discovery for Huntington's Disease

Drug Discovery Today

Volumn 14, Issue 9-10, 2009, Pages 453-464

  Fecke, Wolfgang ^a   Gianfriddo, Marco ^a   Gaviraghi, Giovanni ^a   Terstappen, Georg C ^a   Heitz, Freddy ^a  

^a Siena Biotech SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HUNTINGTIN;

AMINO TERMINAL SEQUENCE; BRAIN SLICE; CELL ASSAY; CELL DEATH; DRUG RESEARCH; EXPERIMENTAL MODEL; GENE MUTATION; HUMAN; HUNTINGTON CHOREA; IN VITRO STUDY; IN VIVO STUDY; MAMMAL CELL; MOLECULAR SIZE; NONHUMAN; NUCLEOTIDE REPEAT; PROTEIN AGGREGATION; PROTEIN DETERMINATION; REVIEW; TRANSCRIPTION REGULATION; YEAST;

ANIMALS; CELL AGGREGATION; CELL DEATH; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HUMANS; HUNTINGTON DISEASE; MODELS, BIOLOGICAL; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; PROTEIN ARRAY ANALYSIS; SMALL MOLECULE LIBRARIES; TRANSCRIPTION, GENETIC;

EID: 67349122746     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2009.02.006     Document Type: Review

References (101)

1. Stack E.C., and Ferrante R.J. Huntington's disease: progress and potential in the field. Expert Opin. Investig. Drugs 16 (2007) 1933-1953
2. DiFiglia M., et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277 (1997) 1990-1993
3. Sanchez I., et al. Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature 421 (2003) 373-379
4. Arrasate M., et al. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431 (2004) 805-810
5. Grunewald T., and Beal M.F. Bioenergetics in Huntington's disease. Ann. N.Y. Acad. Sci. 893 (1999) 203-213
6. Taylor-Robinson S.D., et al. Proton magnetic resonance spectroscopy in Huntington's disease: evidence in favour of the glutamate excitotoxic theory. Mov. Disord. 11 (1996) 167-173
7. Luthi-Carter R., et al. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum. Mol. Genet. 9 (2000) 1259-1271
8. Chan E.Y., et al. Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease. Hum. Mol. Genet. 11 (2002) 1939-1951
9. Kuhn A., et al. Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum. Mol. Genet. 16 (2007) 1845-1861
10. Cha J.H. Transcriptional signatures in Huntington's disease. Prog. Neurobiol. 83 (2007) 228-248
11. Dunah A.W., et al. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science 296 (2002) 2238-2243
12. Li S.H., et al. Interaction of Huntington disease protein with transcriptional activator Sp1. Mol. Cell Biol. 22 (2002) 1277-1287
13. Steffan J.S., et al. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 6763-6768
14. Nucifora Jr. F.C., et al. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 291 (2001) 2423-2428
15. Wyttenbach A., et al. Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease. Hum. Mol. Genet. 10 (2001) 1829-1845
16. Stack E.C., et al. Modulation of nucleosome dynamics in Huntington's disease. Hum. Mol. Genet. 16 (2007) 1164-1175
17. Bennett E.J., et al. Global changes to the ubiquitin system in Huntington's disease. Nature 448 (2007) 704-708
18. Ravikumar B., et al. Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. Hum. Mol. Genet. 11 (2002) 1107-1117
19. Friedlander R.M. Apoptosis and caspases in neurodegenerative diseases. N. Engl. J. Med. 348 (2003) 1365-1375
20. Harper S.Q., et al. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 5820-5825
21. Khoshnan A., et al. Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 1002-1007
22. Wilhelmus M.M., et al. Tissue transglutaminase: a novel pharmacological target in preventing toxic protein aggregation in neurodegenerative diseases. Eur. J. Pharmacol. 585 (2008) 464-472
23. Ryu H., et al. The therapeutic role of creatine in Huntington's disease. Pharmacol. Ther. 108 (2005) 193-207
24. Matthews R.T., et al. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 8892-8897
25. Steffan J.S., et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 413 (2001) 739-743
26. Hockly E., et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 2041-2046
27. Ferrante R.J., et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J. Neurosci. 23 (2003) 9418-9427
28. Toulmond S., et al. Neuroprotective effects of M826, a reversible caspase-3 inhibitor, in the rat malonate model of Huntington's disease. Br. J. Pharmacol. 141 (2004) 689-697
29. Heitz F., et al. Drug discovery and development for Huntington's disease-an orphan indication with high medical need. IDrugs 11 (2008) 653-660
30. Hersch S.M., and Rosas H.D. Neuroprotection for Huntington's disease: ready, set, slow. Neurotherapeutics 5 (2008) 226-236
31. Scherzinger E., et al. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell 90 (1997) 549-558
32. Heiser V., et al. Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington's disease therapy. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 6739-6744
33. Tanaka M., et al. Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nat. Med. 10 (2004) 148-154
34. Heiser V., et al. Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington's disease by using an automated filter retardation assay. Proc. Natl. Acad. Sci. U. S. A. 99 Suppl. 4 (2002) 16400-16406
35. Jimonet P., et al. Riluzole series. Synthesis and in vivo 'antiglutamate' activity of 6-substituted-2-benzothiazolamines and 3-substituted-2-imino-benzothiazolines. J. Med. Chem. 42 (1999) 2828-2843
36. Berthelier V., et al. A microtiter plate assay for polyglutamine aggregate extension. Anal. Biochem. 295 (2001) 227-236
37. Wang J., et al. Reversal of a full-length mutant huntingtin neuronal cell phenotype by chemical inhibitors of polyglutamine-mediated aggregation. BMC Neurosci. 6 (2005) 1
38. Hamuro L., et al. Optimization of a polyglutamine aggregation inhibitor peptide (QBP1) using a thioflavin T fluorescence assay. Assay Drug Dev. Technol. 5 (2007) 629-636
39. Nagai Y., et al. Inhibition of polyglutamine protein aggregation and cell death by novel peptides identified by phage display screening. J. Biol. Chem. 275 (2000) 10437-10442
40. Krobitsch S., and Lindquist S. Aggregation of huntingtin in yeast varies with the length of the polyglutamine expansion and the expression of chaperone proteins. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 1589-1594
41. Zhang X., et al. A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 892-897
42. Murphy R.C., and Messer A. Gene transfer methods for CNS organotypic cultures: a comparison of three nonviral methods. Mol. Ther. 3 (2001) 113-121
43. Murphy R.C., and Messer A. A single-chain Fv intrabody provides functional protection against the effects of mutant protein in an organotypic slice culture model of Huntington's disease. Brain Res. Mol. Brain Res. 121 (2004) 141-145
44. Varma H., et al. High throughput screening for neurodegeneration and complex disease phenotypes. Comb. Chem. High Throughput Screen. 11 (2008) 238-248
45. Smith D.L., et al. Inhibition of polyglutamine aggregation in R6/2 HD brain slices-complex dose-response profiles. Neurobiol. Dis. 8 (2001) 1017-1026
46. Pollitt S.K., et al. A rapid cellular FRET assay of polyglutamine aggregation identifies a novel inhibitor. Neuron 40 (2003) 685-694
47. Shao J., et al. Phosphorylation of profilin by ROCK1 regulates polyglutamine aggregation. Mol. Cell Biol. 28 (2008) 5196-5208
48. Desai U.A., et al. Biologically active molecules that reduce polyglutamine aggregation and toxicity. Hum. Mol. Genet. 15 (2006) 2114-2124
49. Gong B., et al. Time-lapse analysis of aggregate formation in an inducible PC12 cell model of Huntington's disease reveals time-dependent aggregate formation that transiently delays cell death. Brain Res. Bull. 75 (2008) 146-157
50. Scotter E.L., et al. High throughput quantification of mutant huntingtin aggregates. J. Neurosci. Methods 171 (2008) 174-179
51. Weiss A., et al. Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntington's disease. J. Neurochem. 104 (2008) 846-858
52. Feng B.Y., et al. Small-molecule aggregates inhibit amyloid polymerization. Nat. Chem. Biol. 4 (2008) 197-199
53. Sarkar S., et al. Small molecules enhance autophagy and reduce toxicity in Huntington's disease models. Nat. Chem. Biol. 3 (2007) 331-338
54. Apostol B.L., et al. A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 5950-5955
55. Coufal M., et al. Discovery of a novel small-molecule targeting selective clearance of mutant huntingtin fragments. J. Biomol. Screen. 12 (2007) 351-360
56. Bae B.I., et al. p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease. Neuron 47 (2005) 29-41
57. Yamanaka T., et al. Mutant Huntingtin reduces HSP70 expression through the sequestration of NF-Y transcription factor. EMBO J. 27 (2008) 827-839
58. Doi H., et al. RNA-binding protein TLS is a major nuclear aggregate-interacting protein in huntingtin exon 1 with expanded polyglutamine-expressing cells. J. Biol. Chem. 283 (2008) 6489-6500
59. Obrietan K., and Hoyt K.R. CRE-mediated transcription is increased in Huntington's disease transgenic mice. J. Neurosci. 24 (2004) 791-796
60. Qiu Z., et al. Sp1 is up-regulated in cellular and transgenic models of Huntington disease, and its reduction is neuroprotective. J. Biol. Chem. 281 (2006) 16672-16680
61. Sugars K.L., et al. Decreased cAMP response element-mediated transcription: an early event in exon 1 and full-length cell models of Huntington's disease that contributes to polyglutamine pathogenesis. J. Biol. Chem. 279 (2004) 4988-4999
62. Benn C.L., et al. Huntingtin modulates transcription, occupies gene promoters in vivo, and binds directly to DNA in a polyglutamine-dependent manner. J. Neurosci. 28 (2008) 10720-10733
63. Kazantsev A.G., and Hersch S.M. Drug targeting of dysregulated transcription in Huntington's disease. Prog. Neurobiol. 83 (2007) 249-259
64. Zala D., et al. Progressive and selective striatal degeneration in primary neuronal cultures using lentiviral vector coding for a mutant huntingtin fragment. Neurobiol. Dis. 20 (2005) 785-798
65. Piccioni F., et al. A screen for drugs that protect against the cytotoxicity of polyglutamine-expanded androgen receptor. Hum. Mol. Genet. 13 (2004) 437-446
66. Aiken C.T., et al. A cell-based screen for drugs to treat Huntington's disease. Neurobiol. Dis. 16 (2004) 546-555
67. Wang W., et al. Compounds blocking mutant huntingtin toxicity identified using a Huntington's disease neuronal cell model. Neurobiol. Dis. 20 (2005) 500-508
68. Varma H., et al. Selective inhibitors of death in mutant huntingtin cells. Nat. Chem. Biol. 3 (2007) 99-100
69. Rigamonti D., et al. Wild-type huntingtin protects from apoptosis upstream of caspase-3. J. Neurosci. 20 (2000) 3705-3713
70. Lo D.C. Neuronal transfection using particle-mediated gene transfer. Curr. Protoc. Neurosci. (2001) Chapter 3, Unit 3.15
71. Wang J.K., et al. Cardiac glycosides provide neuroprotection against ischemic stroke: discovery by a brain slice-based compound screening platform. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 10461-10466
72. Faber P.W., et al. Polyglutamine-mediated dysfunction and apoptotic death of a Caenorhabditis elegans sensory neuron. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 179-184
73. Jackson G.R., et al. Polyglutamine-expanded human huntingtin transgenes induce degeneration of Drosophila photoreceptor neurons. Neuron 21 (1998) 633-642
74. Marsh J.L., et al. Fly models of Huntington's disease. Hum. Mol. Genet. 2 (2003) R187-R193 12 Spec No
75. Miller V.M., et al. CHIP suppresses polyglutamine aggregation and toxicity in vitro and in vivo. J. Neurosci. 25 (2005) 9152-9161
76. Voisine C., et al. Identification of potential therapeutic drugs for huntington's disease using Caenorhabditis elegans. PLOS ONE 2 (2007) e504
77. Pallos J., et al. Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease. Hum. Mol. Genet. 17 (2008) 3767-3775
78. Nagai Y., et al. Prevention of polyglutamine oligomerization and neurodegeneration by the peptide inhibitor QBP1 in Drosophila. Hum. Mol. Genet. 12 (2003) 1253-1259
79. Flinn L., et al. Zebrafish as a new animal model for movement disorders. J. Neurochem. 106 (2008) 1991-1997
80. Williams A., et al. Novel targets for Huntington's disease in an mTOR-independent autophagy pathway. Nat. Chem. Biol. 4 (2008) 295-305
81. Coyle J.T., and Schwarcz R. Lesion of striatal neurones with kainic acid provides a model for Huntington's chorea. Nature 263 (1976) 244-246
82. Roberts R.C., et al. Intrastriatal injections of quinolinic acid or kainic acid: differential patterns of cell survival and the effects of data analysis on outcome. Exp. Neurol. 124 (1993) 274-282
83. Beal M.F., et al. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J. Neurosci. 13 (1993) 4181-4192
84. Brouillet E., et al. 3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease. J. Neurochem. 95 (2005) 1521-1540
85. Beal M.F., and Ferrante R.J. Experimental therapeutics in transgenic mouse models of Huntington's disease. Nat. Rev. Neurosci. 5 (2004) 373-384
86. Mangiarini L., et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87 (1996) 493-506
87. Van Dellen A., et al. Delaying the onset of Huntington's in mice. Nature 404 (2000) 721-722
88. Van Raamsdonk J.M., et al. Phenotypic abnormalities in the YAC128 mouse model of Huntington disease are penetrant on multiple genetic backgrounds and modulated by strain. Neurobiol. Dis. 26 (2007) 189-200
89. Schilling G., et al. Environmental, pharmacological, and genetic modulation of the HD phenotype in transgenic mice. Exp. Neurol. 187 (2004) 137-149
90. Lloret A., et al. Genetic background modifies nuclear mutant huntingtin accumulation and HD CAG repeat instability in Huntington's disease knock-in mice. Hum. Mol. Genet. 15 (2006) 2015-2024
91. Hockly E., et al. Environmental enrichment slows disease progression in R6/2 Huntington's disease mice. Ann. Neurol. 51 (2002) 235-242
92. Schilling G., et al. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum. Mol. Genet. 8 (1999) 397-407
93. von Horsten S., et al. Transgenic rat model of Huntington's disease. Hum. Mol. Genet. 12 (2003) 617-624
94. Hodgson J.G., et al. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 23 (1999) 181-192
95. Gray M., et al. Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J. Neurosci. 28 (2008) 6182-6195
96. Menalled L.B., et al. Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington's disease knock-in mice. J. Neurosci. 22 (2002) 8266-8276
97. Wheeler V.C., et al. Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. Hum. Mol. Genet. 9 (2000) 503-513
98. Lin C.H., et al. Neurological abnormalities in a knock-in mouse model of Huntington's disease. Hum. Mol. Genet. 10 (2001) 137-144
99. Yang S.H., et al. Towards a transgenic model of Huntington's disease in a non-human primate. Nature 453 (2008) 921-924
100. Terstappen G.C., et al. Target deconvolution strategies in drug discovery. Nat. Rev. Drug Discov. 6 (2007) 891-903
101. Kassner P.D. Discovery of novel targets with high throughput RNA interference screening. Comb. Chem. High Throughput Screen. 11 (2008) 175-184